Related Experiment Video
Updated: May 29, 2026
08:49
Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
Published on: August 2, 2024
Natriuretic peptides in therapy for decompensated heart failure
Natig Gassanov1, Esther Biesenbach, Evren Caglayan
1Department of Internal Medicine III, University of Cologne, Cologne, Germany. Natig.Gassanov@uk-koeln.de
European Journal of Clinical Pharmacology
|September 9, 2011
Summary
Natriuretic peptides offer a promising treatment for acute decompensated heart failure (ADHF), improving symptoms and hemodynamics. This review updates on natriuretic peptides like nesiritide and ularitide for advanced heart failure management.
Area of Science:
- Cardiology and Pharmacology
- Biochemistry and Molecular Biology
Background:
- Congestive heart failure (CHF) is a leading cause of hospitalization in older adults, with limited progress in acute decompensated CHF (ADHF) treatment.
- Current ADHF therapies have limitations, highlighting the need for novel therapeutic approaches.
- Natriuretic peptides target key pathophysiological mechanisms in CHF, including vasodilation, diuresis, and renin-angiotensin-aldosterone system inhibition.
Purpose of the Study:
- To review the therapeutic potential of natriuretic peptides in advanced congestive heart failure.
- To provide an update on nesiritide and ularitide for managing decompensated heart failure.
Main Methods:
- Review of recent clinical studies and literature on natriuretic peptides in heart failure.
- Analysis of the mechanism of action, efficacy, and limitations of current and emerging natriuretic peptide therapies.
Main Results:
- Nesiritide, a recombinant B-type natriuretic peptide, improves dyspnea and hemodynamics in ADHF.
- Ularitide, a synthetic natriuretic peptide, shows potential in managing decompensated heart failure.
- Natriuretic peptides offer a promising therapeutic avenue due to their vasodilatory, diuretic, and counter-regulatory effects.
Conclusions:
- Natriuretic peptides represent a significant advancement in the treatment of acute decompensated heart failure.
- Further research and clinical application of nesiritide and ularitide may improve outcomes for patients with advanced CHF.
More Related Videos
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include: